Denali therapeutics announces continued progress in dnl310 (etv:ids) program for mps ii (hunter syndrome) supporting planned initiation of phase 2/3 clinical trial

South san francisco, calif., feb. 10, 2022 (globe newswire) -- denali therapeutics inc. (nasdaq: dnli), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (bbb) for neurodegenerative diseases, today announced that new longer-term data from an ongoing phase 1/2 clinical trial of dnl310 (etv:ids) are being presented today at worldsymposium™. dnl310 is an investigational brain-penetrant enzyme replacement therapy intended to treat both central nervous system (cns) and peripheral manifestations of mps ii (hunter syndrome).
DNLI Ratings Summary
DNLI Quant Ranking